Semax dosage and protocol
Semax dosage on this page comes only from published human studies, each linked to its source, with how it was given and to whom. Semax is a synthetic seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro), an analog of the adrenocorticotropic hormone fragment 4-10. The Russian literature describes it as a nootropic drug given as nasal drops.
What Semax is
Semax is a synthetic seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro), an analog of the adrenocorticotropic hormone fragment 4-10. The Russian literature describes it as a nootropic drug given as nasal drops. (5)
Other names and codes used in the research: Met-Glu-His-Phe-Pro-Gly-Pro, semax (heptapeptide).
How Semax works
Semax is the 4 to 7 piece of the hormone ACTH with three extra amino acids on the end. The point of the change is that it keeps the brain effects of the hormone without the hormone work: it does not drive steroid output or skin pigment cells. (6)
There is a measured binding site. Using a radioactive version of the peptide, a Moscow group found binding in rat forebrain membranes that was specific, reversible and needed calcium, with a dissociation constant of about 2.4 nanomolar. (7)
That binding looked like a real receptor interaction rather than sticking to a surface, since it depended on time and could be displaced. (7)
The best-supported downstream step is growth factor output. In rats given 50 and 250 micrograms per kilogram into the nose, BDNF protein in the basal forebrain rose within three hours, with no change in the cerebellum. (7)
In the hippocampus the same effect is modest in size: a single dose raised BDNF protein by about 1.4 times, with larger changes in the messenger RNA that codes for it and for its receptor. (8)
It also acts directly on nerve cell channels. In isolated cerebellar neurons the peptide more than doubled the current flowing through GABA receptors, a raise of about 147 percent. (9)
In hippocampal neurons it pushed the other way, cutting the current through glycine receptors to between 68 and 43 percent of normal depending on concentration. The same peptide is not doing the same thing everywhere in the brain. (9)
Both of those channel effects built up slowly and did not wash out, which the authors read as second messengers doing the work rather than the peptide sitting on the channel. (9)
On brain chemistry it leans serotonin. The serotonin breakdown product in rat striatum rose to 180 percent over one to four hours, while dopamine itself did not budge. (10)
Dopamine only moved when a stimulant was on board, and then the peptide amplified it, which is the finding behind the abuse-potential question raised later by US regulators. (10)
A 2025 Chinese study in mice with spinal cord injury traced the peptide's effect to a specific enzyme that strips ubiquitin tags from proteins, naming USP18 as the link. (11)
FDA's own summary of the mechanism is that it does several things at once and none of them are well understood. (12)
Where Semax came from
Semax is a registered medicine in Russia, which sets it apart from most peptides sold online. FDA's 2026 review states the registration and the two strengths it is sold in. (12)
It is not recognised elsewhere. There is no monograph for it in the European, Japanese or International pharmacopoeias. (12)
The development programme was long and open about its aim: a 1997 Russian paper sums up fifteen years of work on the peptide as a memory and attention drug. (13)
That same 1997 summary made the safety claim that still follows the peptide around, and it is worth reading as the developers' own assessment rather than as a trial result. (13)
On 23 and 24 July 2026 the US compounding advisory committee reviewed this peptide, alongside epitalon and five others, for possible inclusion on the list of substances pharmacies may compound. (14)
The uses FDA actually examined were stroke-related brain damage and pain from migraine and trigeminal neuralgia. In the United States the peptide is sold far more widely than that, through clinics and online retailers. (12)
No regulated US compounder claims it. No outsourcing facility has reported making a semax product to FDA since 2019. (12)
In Russian paediatric neurology it still sits in the weaker evidence tier. A 2026 expert council on attention deficit disorder put it in group B, the limited-evidence group, beside cortexin and several other domestic products. (15)
Semax dosage on record
Every Semax dosage below comes from a product label or a published human study. The grey line under each dose is the source's own wording, so you can check it. Doses from different studies are not interchangeable: look at how it was given, to whom and for how long.
| Dose | Type | How often | How long | Who |
|---|---|---|---|---|
| 12 mgOpen-label trial in motor neuron disease; 1% solution given into the nose (intranasal)Source text: “The drug was administered intranasally in two 10-day-long courses with 2-weeks break in daily dose of 12 mg.” | Human study | daily dose | two 10-day courses with a 2-week break | 27 patients with definite, probable or possible motor neuron disease (3) |
| 2 to 4 drops of 1% solutionPeptic ulcer study, added to standard ulcer drugs; 1% solution given into the nose (intranasal). The abstract gives drops, not mgSource text: “intranasal Semax (1% solution, 2-4 drops 3 times a day for 10 days)” | Human study | 3 times a day | 10 days | patients with refractory peptic ulcers; number not given in the abstract (2) |
| 12 mgAcute hemispheric ischemic stroke, added to intensive therapy; route not stated in the abstract. Dose for strokes of moderate severitySource text: “The most effective daily doses were 12 mg for patients with strokes of moderate severity and 18 mg for patients with severe strokes (treatment course--5 and 10 days).” | Human study | daily dose | 5 or 10 days | 30 patients on Semax, compared with 80 patients on conventional therapy (1) |
| 18 mgAcute hemispheric ischemic stroke, added to intensive therapy; route not stated in the abstract. Dose for severe strokesSource text: “The most effective daily doses were 12 mg for patients with strokes of moderate severity and 18 mg for patients with severe strokes (treatment course--5 and 10 days).” | Human study | daily dose | 5 or 10 days | same study (1) |
| 6000 mcgRehabilitation after ischemic stroke; route not stated in the abstractSource text: “Standard regimen of semax included 2 courses (6000 mcg/day) for 10 days with 20 day interval.” | Human study | per day | 2 courses of 10 days with a 20-day interval | 110 patients after ischemic stroke, divided into subgroups with and without Semax; the abstract does not say how many received it (4) |
How to reconstitute Semax
Semax comes as a dry powder (5 mg vials). Reconstituting it means adding bacteriostatic water so it can be drawn into a syringe. The water does not change how much Semax is in the vial, only how strong each mL is, so it decides how many syringe units a dose takes.
| Vial | Water | Strength | What 10 units holds | Doses between 5 and 100 units |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 500 mcg in every 10 units | 250 mcg to 5 mg |
| 5 mg | 2 mL | 2.5 mg/mL | 250 mcg in every 10 units | 125 mcg to 2.5 mg |
| 5 mg | 3 mL | 1.667 mg/mL | 167 mcg in every 10 units | 83 mcg to 1.67 mg |
The last column is the range of doses that land between the 5 unit mark (small marks are hard to read) and the 100 unit mark of a 1 mL U-100 syringe for that mix. All of it is arithmetic.
Reconstitution steps
- Wash your hands, work in a clean area and set out the Semax vial, bacteriostatic water, a sterile syringe, alcohol pads and a sharps container (17).
- Check the vial and the water: right product, in date, intact cap (17).
- Wipe both rubber tops with an alcohol pad and let them dry (17).
- Draw the water amount you picked from the table into the syringe.
- Push the needle through the Semax vial stopper and let the water in slowly.
- Move the vial in a circle until the powder is fully dissolved. Do not shake it (18).
- Check the liquid. MedlinePlus says not to use it if it has changed color, has floating pieces or is cloudy (17).
- Write the date you mixed it on the vial (17), and note the water amount so every later draw uses the same numbers.
After mixing
No published storage data exists for mixed Semax; the bacteriostatic water label says not to store a mixed drug unless its maker says you can (16).
For any other vial size, water amount or dose, use the Semax reconstitution calculator.
Semax dosage and half-life
There is no human pharmacokinetic data for this peptide by any route, which FDA states directly after searching for it in 2026. (12)
Nor is there any published study of it given under the skin, the route sold as an injectable. Everything in the literature is the nose. (12)
The animal numbers are small either way. After a dose into the nose in rats, about 0.093 percent of what was given turned up per gram of brain at two minutes, and roughly four fifths of that was still intact peptide. (19)
By vein it is far worse: no more than about 0.01 percent of the dose reached brain tissue in rats, which is the measurement behind the preference for the nasal route. (20)
It is broken down quickly, and the piece that survives is the three amino acid tail, Pro-Gly-Pro. That fragment has activity of its own, so some effects may not belong to the whole peptide. (19)
The enzymes doing the cutting have been identified in rat serum: peptidases that trim from the head of the chain, plus angiotensin converting enzyme, the same enzyme targeted by common blood pressure drugs. (21)
The three added amino acids do their job. Side by side with the plain hormone fragment, the modified peptide held up better against the other degrading enzymes. (22)
Later work pinned down the first cut: in nasal mucus, brain membranes and rat blood, the only metabolite formed from the peptide was the five amino acid piece left after the first two are removed. (23)
What the Semax research found
In people
- Small human studyAcute ischemic stroke: adding Semax to intensive therapy was reported to speed recovery of neurological function, especially movement. The comparison group was not randomized. (1)Source text: “had some influence on the rate of restoration of the damaged neurological functions”
- Small human studyAfter ischemic stroke: Semax raised plasma BDNF, and the authors linked this to faster functional recovery. (4)Source text: “Administration of semax, regardless of the timing of rehabilitation, increased BDNF plasma levels which remained high during the whole study period.”
- Small human studyMotor neuron disease: intranasal Semax did not change the course of denervation or the clinical ratings. A quality-of-life score improved. (3)Source text: “Semax (1% solution) does not influence either the course of CPD or the dynamics of clinical estimates”
- Small human studyRefractory peptic ulcer: with intranasal Semax added to usual drugs, 89.5% of ulcers had healed at day 14 against 30.8% in the control group. (2)Source text: “On day 14 of treatment ulcer healing was observed in 89.5% patients receiving intranasal Semax”
- Small human studyHealthy volunteers: brain scans taken 5 and 20 minutes after intranasal 1% Semax (14 people) or placebo (10 people) showed a difference in one part of the default mode network. (24)Source text: “A greater volume of the default mode network rostral (medial frontal cortex) subcomponent was detected in the Semax group in comparison with controls.”
- Small human studyChronic cerebrovascular insufficiency (187 patients): the authors reported clinical improvement and a lower risk of stroke and transient ischemic attacks. The abstract does not describe a control group or the dose. (25)Source text: “Semax treatment resulted in significant clinical improvement, stabilization of the disease progress”
- Small human studyOptic nerve disease: Semax was given as nasal drops or by endonasal electrophoresis alongside standard therapy, with a third group as control. The authors reported a favorable effect on the speed of recovery and on vision. No dose in the abstract. (5)Source text: “Addition of semax to therapeutic complex in patients with diseases of the optic nerve had a favorable impact on the intensity and rate of recovery and improved the visual functions.”
- Small human studyFDA counted the whole human record in 2026 and it is small: tens of healthy adults, 69 adults with illnesses and 451 children, across eight references, three of which are only conference abstracts. (12)Source text: “69 adults with medical conditions (including chronic ischemic brain disease, pain due to migraine and trigeminal neuralgia, and peptic ulcer), and 451 children”
- Small human studyOn the stroke use that semax is best known for, FDA's conclusion was that there is not enough evidence to support it, because the only usable submission was a meeting abstract. (12)Source text: “There is insufficient evidence of effectiveness to support use of semax (free base) or semax acetate for cerebral ischemia.”
- Small human studyThe reason is procedural as much as scientific: the stroke papers FDA found were in Russian, and under its own rules they could not be considered without verified translations. (12)Source text: “References regarding the use of semax-related BDSs for cerebral ischemia found by FDA were articles published in Russian”
- Small human studyA 2024 Russian review reaches the opposite verdict on the same literature, reporting the peptide as clinically effective in ischemic stroke both early and in recovery. Which verdict a reader accepts comes down to whether the Russian-language trials count. (26)Source text: “The review of clinical studies indicates that MGHPPGP is clinically effective in the treatment of ischemic stroke both in the acute period of stroke and in the recovery period.”
- Small human studyOn pain, the one study FDA could read reported that a single dose into the nose did nothing measurable in classic trigeminal neuralgia: no change in pain ratings, sensation thresholds or nerve recordings. (12)Source text: “there were no changes in the characteristics of pain in the MPST nor changes in sensation or pain thresholds”
- Small human studyThe authors of that study drew the blunt conclusion that the peptide is not a painkiller in its own right. (12)Source text: “no significant changes in TSEP were observed after a single intranasal administration of semax. This observation indicates that semax does not exhibit analgesic activity by itself”
- Small human studyIn the migraine arm of the same study, 4 of 12 people had their headache stop within two hours and the other 8 reported it only easing, with no control group to compare against. (12)Source text: “Four subjects out of twelve (33%) reported cessation of headache pain 90-120 minutes after semax administration”
- Small human studyA 2026 Russian eye study in 50 patients having glaucoma surgery is the newest human data. Both groups got the peptide; the group that also had electrical and magnetic stimulation held their visual field gain for six months. (27)Source text: “The control group received 0.1% Semax nasal drops twice daily for 10 days.”
- Small human studyIn the group given nasal drops alone, the visual field measure slid back to where it started within three months, which is the most honest reading of nasal drops without the rest of the package. (27)Source text: “In the control group, MD returned to baseline values by month 3.”
- Small human studyTwo structural eye measures in that study did not change at all, so the benefit was in function rather than in tissue. (27)Source text: “Analysis of VFI, AvgRNFL, and GCC revealed no statistically significant differences.”
- Small human studyA second 2026 eye study, in 42 patients after retinal detachment surgery, compared the peptide driven in by electrophoresis against ordinary nasal drops. Electrophoresis came out ahead at six months. (28)Source text: “Patients in group 1 showed a higher level of recovery of functional BCVA and fundus microperimetry parameters compared with patients in group 2 by month 6 of the follow-up.”
- Small human studyThat design matters for anyone buying a nasal spray: the comparison group in these studies is the nasal route, and it is the weaker arm. (28)Source text: “Group 2 included 19 patients who received nasal instillations of 0.1% Semax drops starting on day 5 after surgery.”
- Small human studyIn 60 patients with optic nerve damage from poor blood supply, a package of treatments including the peptide by electrophoresis was rated 94 percent effective at one week and still 83 percent at six months. (29)Source text: “the therapeutic efficacy in a week after the end of treatment was 94%, in 12 weeks - in 88% and in 24 weeks - 83%”
- Small human studyThe control group in that study was given a vitamin complex, and reached 30 to 42 percent. The comparison is between a four-part treatment package and vitamins, not between the peptide and placebo. (29)Source text: “while in patients of the control group for all studied indicators showed only a positive trend and therapeutic efficacy did not exceed 30-42%”
- Small human studyIn 114 patients with early diabetic eye disease, the best and longest-lasting results again came from the electrophoresis group rather than from nasal drops. (30)Source text: “The most pronounced and long-standing (up to 12 months) positive effect on the visual function was documented in the main group.”
- Small human studyThe eye work goes back to 2001, when a Russian group reported the peptide beating standard nerve-protection treatment in glaucoma patients whose eye pressure was already controlled. (31)Source text: “Electrophysiological and computer methods of examination demonstrated the advantages of new therapy over traditional neuroprotective treatment for glaucoma.”
- Small human studyA 2015 study in 118 people with psoriasis and metabolic syndrome is the only use outside the brain and eye with human data: adding the peptide lowered cholesterol, triglycerides and LDL where standard treatment did not. (32)Source text: “led to a decrease in the initially elevated serum levels of total cholesterol, triglycerides, LDL cholesterol”
- Small human studyIn acute stroke patients, a 1999 Russian study reported the peptide shifting the balance of inflammatory signals in blood. The abstract's own grouping of those signals is unorthodox, which is a reason to treat the result cautiously. (33)Source text: “Shifting neuromediatory balance toward a prevalence of the antiinflammatory agents (interleukin-10, tumor necrosis factor-alpha) over the factors maintaining the inflammation (interleukin-8, C-reactive protein)”
In animals and in the lab
These results come from animals or cells. They show what researchers are looking at, not what Semax does in people.
- Animal studyIn mice with spinal cord injury, a 2025 study in a mainstream pharmacology journal reported better functional recovery and less inflammatory cell death with the peptide. (11)Source text: “Semax improved SCI functional recovery and inhibited LMP-related pyroptosis in SCI mice and neuroinflammation models, by decreasing oxidative stress.”
- Animal studyIn rats under weeks of unpredictable stress, the peptide reversed the loss of interest in sweet water, the weight-gain slowdown, the enlarged adrenal glands and the drop in hippocampal BDNF. (34)Source text: “chronic treatment with Semax and MTII reversed or substantially attenuated CUS-induced anhedonia, BW gain suppression, adrenal hypertrophy and a decrease in the hippocampal levels of BDNF”
- Animal studyThe same study found nothing on the other standard depression test, which is the kind of split result that gets left out of summaries. (34)Source text: “In the forced swim test, no effects of the CUS procedure or peptides on the duration of rat immobility were detected.”
- Lab studyIn human stem-cell-derived nerve cells exposed to hydrogen peroxide, the peptide's protective effect was about 40 percent, well behind the best compound tested. (35)Source text: “the effect of melanocortin Semax was ~40%”
- Lab studyThat same screen looked for harm and found none: no compound tested, this peptide included, was toxic to the cells or to embryonic development in the dish. (35)Source text: “None of the tested compounds displayed cyto- or embryotoxicity.”
- Animal studyIn mice with advanced breast tumours, late-life treatment shrank the tumours and extended average lifespan by about 68 percent. FDA notes the study used one fixed amount, only female mice, and lasted under three months. (12)Source text: “The semax treatment also prolonged the mean lifespan of SHK mice by ~68%.”
- Animal studyRoute decides what the peptide does in animals. Given into the abdomen it worked as both a memory aid and a painkiller. (36)Source text: “It was shown that Semax exerts nootropic and analgesic activities following intraperitoneal administration.”
- Animal studyGiven into the nose, the learning effect was stronger than by injection but the pain effect disappeared entirely, which lines up with the human finding that it is not a painkiller by the nasal route. (36)Source text: “The peptide failed to affect the animal pain sensitivity following intranasal administration as opposed to intraperitoneal administration.”
Semax dosage and side effects
What labels and human studies report. A short or small study can miss rare side effects, so an empty list is not proof of safety.
- In the 187-patient cerebrovascular study the authors reported few side effects and good tolerance, including in older patients. No figures are given in the abstract. (25)
- In 73 patients with brain damage after oxygen deprivation, EEG in some cases showed episodes of paroxysmal activity after a Semax dose, and the authors advised EEG monitoring at the first dose. The abstract calls the dose an injection and gives no route or amount. (37)
- FDA says it has no, or limited, safety information for the proposed routes and names immune reactions from aggregation and peptide impurities as possible risks of compounded product. (38)
- There is now one adverse event report on the US federal database for this peptide, logged in a search FDA ran to 3 December 2025. It came directly from a consumer rather than a doctor or company. (12)
- The report describes eye pain and burning after using 0.1 percent nasal drops bought online. (12)
- It was not a passing irritation. The person reported being admitted to hospital and said the eye pain had still not resolved a year later. (12)
- FDA flags a bleeding risk that follows from the peptide's own reported anticoagulant action, especially for people already prone to bleeding or on blood-thinning medicines. (12)
- A second flag is abuse potential, raised because the peptide amplified amphetamine's effect on dopamine in mice, the kind of response drugs of abuse produce. (12)
- Against those flags there is no toxicity programme to check them against: no single-dose toxicity study was found. (12)
- No test of DNA damage was found either, and no repeat-dose study, so long-term use has no safety data behind it. (12)
- Across the human studies FDA could read, side effects were mostly simply not reported. One study said none were seen; in all the others the question went unaddressed. (12)
Animal safety findings
These come from animal studies, not people, but they are the only safety data on record for some outcomes.
- In mice with spinal cord injury, a 2025 study in a mainstream pharmacology journal reported better functional recovery and less inflammatory cell death with the peptide. (11)
- That same screen looked for harm and found none: no compound tested, this peptide included, was toxic to the cells or to embryonic development in the dish. (35)
- In mice with advanced breast tumours, late-life treatment shrank the tumours and extended average lifespan by about 68 percent. FDA notes the study used one fixed amount, only female mice, and lasted under three months. (12)
Injecting under the skin
General steps for an injection under the skin, from MedlinePlus (39). Labels for approved products give their own instructions, which come first.
- Pick a site: the belly (below the ribs, above the hip bones and at least 2 inches from the belly button), the outer upper thigh, or the back or side of the upper arm.
- Move to a new spot each time, at least 1 inch from the last one. MedlinePlus says this keeps the skin healthy and helps the body absorb the medicine.
- Wash your hands with soap and running water for at least 1 minute, dry them, then clean the skin with an alcohol pad and let it dry.
- Pinch about an inch of skin and fat, put the needle in quickly at 90 degrees (45 degrees if there is little fat), let go of the skin and push the plunger all the way.
- Pull the needle out, put it straight into a sharps container, and press clean gauze on the spot for a few seconds. Never reuse a needle or syringe.
- Some soreness is expected. MedlinePlus says to contact a health care provider for signs of infection such as redness, swelling, red streaks or fever.
To draw the right amount, use the Semax calculator and the drawing steps on that page.
Is Semax banned in sport?
On the prohibited list in force from 1 January 2027, peptides are named as a class in S0, the category banned at all times, so a peptide no longer has to be listed by name to be caught. (40)
The S0 definition turns on having no approval for human use from any health authority anywhere. Semax is an awkward fit for that wording, since it is a registered medicine in Russia, but the class-wide peptide wording does not depend on it. (40)
Semax is not one of the peptides the US anti-doping agency names as examples, and the agency says an unnamed peptide should still be treated as prohibited. (40)
The agency's blunt summary of the current market is that the surge in peptide use carries both sanction and health risk. (40)
Is Semax legal in the US and Canada?
FDA page content current as of 2026-04-22. openFDA searches of Drugs@FDA and of drug labels for semax returned no match on 2026-10-10.
Advisory dated 2025-08-01. Drug Product Database searches for semax by ingredient and by brand returned no rows on 2026-10-10 (S12).
What is still unknown
- The human data are for Semax given into the nose as a 1% solution, not injected. No human study of injected Semax with a stated dose was found.
- Not approved in the US or Canada as of the check date. Papers describe it as a Russian drug (S1), but the Russian register could not be checked.
- Most of the human studies found are in Russian-language journals, are small or lack a randomized control, and several share co-authors. None is registered on ClinicalTrials.gov.
- A Belgian public health laboratory that identified Semax and Selank in seized products wrote that, to its knowledge, they had not completed any clinical trials, and that they are sold online as powder for injection or in nasal sprays (S9).
- Health Canada named Semax among unauthorized injectable peptide drugs seized from an online seller (S11).
- FDA compounding status: on the FDA page current as of 2026-04-22, Semax is not in the table of substances now in category 2. It is in a separate list of substances that were in category 2 and were then withdrawn by their nominators (S10).
- No human study of Semax injected under the skin or into muscle with a stated dose.
- Route for the two stroke studies (S4, S5): not stated in their abstracts, in English or in the Russian publisher abstract.
- No human half-life or pharmacokinetic figure. A PubMed search for semax with pharmacokinetics, half-life or bioavailability returned only rat and test-tube studies.
- No label was retrieved. The Russian state register of medicines responded, but its search needs a captcha, so the Russian registration, strengths and label dose are not recorded here and the products list is empty.
- No trial registered on ClinicalTrials.gov: a search for semax as the intervention returned no studies.
- Not named on the WADA Prohibited List (page checked 2026-10-10, S13). The list also has an open class, S0, for substances with no current approval by any governmental health authority for human therapeutic use; whether it applies to this compound was not determined here.
- No human pharmacokinetic study exists for any route, so there is no measured half-life, blood level or bioavailability in people (X1).
- No published study has given semax under the skin or into muscle, which is how the injectable products on sale are meant to be used (X1).
- No acute toxicity study, no repeat-dose toxicity study, no genotoxicity testing and no two-year cancer study was identified by FDA.
- Abuse potential has not been tested, despite the animal finding that the peptide amplifies amphetamine's effect on dopamine (X1).
- The bleeding risk that follows from its reported anticoagulant action has never been studied in people, including in people on blood thinners (X1).
- The 2026 eye studies cannot separate the peptide from the rest of the treatment package: the better-performing arms added electrical and magnetic stimulation and a helium-oxygen mixture (X3, X5).
- Whether the Russian stroke trials count is unresolved: FDA set them aside for lack of verified translations (X1) while a 2024 Russian review treats them as showing clinical effectiveness (X10).
- Much of what is measured may belong to the fragment rather than the peptide, since the surviving metabolite Pro-Gly-Pro has activity of its own (X15).
- The one human harm report on file, hospitalisation with unresolved eye pain after online nasal drops (X1), has no follow-up and no product testing attached to it, so neither cause nor contents are established.
- The WADA prohibited list PDF could not be opened in this session (the site returned an empty response), so sport status is quoted from the US anti-doping agency's advisory about that list.
Semax dosage questions
What Semax dosage was used in human studies?
12 mg, daily dose; 2 to 4 drops of 1% solution, 3 times a day; 12 mg, daily dose; 18 mg, daily dose. Each is listed with its study on this page.
How often was Semax given?
In the sources on this page: 3 times a day; daily dose; per day.
How long were Semax courses?
In the sources on this page: 10 days; 2 courses of 10 days with a 20-day interval; 5 or 10 days; two 10-day courses with a 2-week break.
Is Semax approved?
Not FDA approved. FDA lists semax (heptapeptide) among bulk substances that were in compounding category 2 and whose nominations were then withdrawn. No Semax product in the Health Canada Drug Product Database. Health Canada named Semax among unauthorized injectable peptide drugs seized from an online seller.
What side effects of Semax have been reported?
In the 187-patient cerebrovascular study the authors reported few side effects and good tolerance, including in older patients. No figures are given in the abstract. In 73 patients with brain damage after oxygen deprivation, EEG in some cases showed episodes of paroxysmal activity after a Semax dose, and the authors advised EEG monitoring at the first dose. The abstract calls the dose an injection and gives no route or amount.
Is Semax banned in sport?
On the prohibited list in force from 1 January 2027, peptides are named as a class in S0, the category banned at all times, so a peptide no longer has to be listed by name to be caught.
How many units of Semax do I draw?
Use the Semax calculator: pick your vial, water and dose, and it gives the units on a U-100 insulin syringe.
Sources
- Gusev EI et al. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova 1997. PubMed 11517472
- Ivanikov IO et al. Therapy of peptic ulcer with semax peptide. Bull Exp Biol Med 2002. PubMed 12459874
- Serdiuk AV et al. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zh Nevrol Psikhiatr Im S S Korsakova 2007. PubMed 18379501
- Gusev EI et al. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova 2018. PubMed 29798983
- Polunin GS et al. [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]. Vestn Oftalmol 2000. PubMed 10741256
- Ponomareva-Stepnaia MA et al. [Hormonal activity of the ACTH(4-10) analog--a prolonged-action stimulant of learning]. Biull Eksp Biol Med 1986. PubMed 3006824
- Dolotov OV et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem 2006. PubMed 16635254
- Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006. PubMed 16996037
- Sharonova IN et al. Modulation of GABA- and Glycine-Activated Ionic Currents with Semax in Isolated Cerebral Neurons. Bull Exp Biol Med 2018. PubMed 29577196
- Eremin KO et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res 2005. PubMed 16362768
- Liu R et al. Semax peptide targets the mu opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Br J Pharmacol 2025. PubMed 40692165
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24 2026: Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate). 2026. fda.gov
- Asmarin IP et al. [A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)]. Zh Vyssh Nerv Deiat Im I P Pavlova 1997. PubMed 9173745
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. 2026. fda.gov
- Lapochkin OL et al. [Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents]. Zh Nevrol Psikhiatr Im S S Korsakova 2026. PubMed 42910684
- Bacteriostatic Water for Injection, USP (Hospira) label. DailyMed
- MedlinePlus, Drawing medicine out of a vial (reviewed 14 Jan 2026). medlineplus.gov
- Egrifta WR (tesamorelin) US prescribing information, section 2.2. DailyMed
- Shevchenko KV et al. [Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration]. Bioorg Khim 2006. PubMed 16523722
- Potaman VN et al. Entry of the synthetic ACTH(4-10) analogue into the rat brain following intravenous injection. Neurosci Lett 1991. PubMed 1652713
- Potaman VN et al. Degradation of ACTH/MSH(4-10) and its synthetic analog semax by rat serum enzymes: an inhibitor study. Peptides 1993. PubMed 8392718
- Potaman VN et al. N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes. Biochem Biophys Res Commun 1991. PubMed 1851003
- Shevchenko KV et al. [Proteolysis of simple glyprolines by leucine aminopeptidase and enzymes from nasal slime, brain membranes, and rat blood]. Bioorg Khim 2013. PubMed 24397030
- Lebedeva IS et al. Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med 2018. PubMed 30225715
- Gusev EI et al. [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zh Nevrol Psikhiatr Im S S Korsakova 2005. PubMed 15792140
- Spirin NN et al. [Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and rehabilitation of patients with ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova 2024. PubMed 39166935
- Yusef Y et al. [Changes in retinal light sensitivity and morphometry during surgical treatment of primary glaucoma with physiotherapeutic stimulation]. Vestn Oftalmol 2026. PubMed 42885627
- Sheludchenko VM et al. [Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome]. Vestn Oftalmol 2026. PubMed 42366656
- Dragon AK et al. [Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis]. Vopr Kurortol Fizioter Lech Fiz Kult 2022. PubMed 36083821
- Nazarova GA et al. [The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy]. Vopr Kurortol Fizioter Lech Fiz Kult 2013. PubMed 24437205
- Kurysheva NI et al. [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone]. Vestn Oftalmol 2001. PubMed 11569188
- Dontsova EV et al. [POSSIBLE DRUG CORRECTION OF LIPID METABOLISM DISTURBANCES ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS]. Eksp Klin Farmakol 2015. PubMed 27051926
- Miasoedova NF et al. [Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova 1999. PubMed 10358912
- Inozemtseva LS et al. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. Eur J Pharmacol 2024. PubMed 39442746
- Novosadova EV et al. The Use of Human Induced Pluripotent Stem Cells for Testing Neuroprotective Activity of Pharmacological Compounds. Biochemistry (Mosc) 2019. PubMed 31760919
- Manchenko DM et al. [Nootropic and analgesic effects of Semax following different routes of administration]. Ross Fiziol Zh Im I M Sechenova 2010. PubMed 21268834
- Alekseeva GV et al. [Use of semax at a follow-up of patients with posthypoxic encephalopathy]. Anesteziol Reanimatol 1999. PubMed 10199046
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. 2026. fda.gov
- MedlinePlus, Subcutaneous (SQ) injections. medlineplus.gov
- Athlete Advisory: What's New on the 2027 WADA Prohibited List?. 2026. usada.org
- Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks. 2025. recalls-rappels.canada.ca
Facts checked 10 Oct 2026 and 11 Nov 2026 against the sources above. This page reports what labels and published studies used. It is not medical advice: talk to a licensed prescriber before you start, stop or change anything.